scholarly journals National prevalence and outcomes of different mitral valve interventions for mitral regurgitation among patients with cardiogenic shock: an analysis of the national readmission database 2010–2018

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
S Aldrugh ◽  
N Kakouros ◽  
W Qureshi
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Hospital Mortality ◽  
Cardiogenic Shock ◽  
Medical Therapy ◽  
Readmission Rate ◽  
Invasive Approach ◽  
Non Invasive ◽  
National Prevalence ◽  
National Readmission Database

Abstract Background Prevalence and outcome data of mitral valve (MV) interventions for severe mitral regurgitation (MR) in the setting of cardiogenic shock (CS) is limited. Purpose Our aim is to study the national prevalence, mortality, and outcomes of three mitral valve interventions (transcatheter mitral valve (MitraClip), surgical mitral valve repair (sMVR), and surgical mitral valve replacement (sMVr)) in patients with severe MR and CS, and how they compare to a non-invasive medical approach to management. Methods Patients with concomitant severe MR and CS were included for the years 2010 - 2018 from the national readmission database. We compared the national prevalence, in hospital mortality, readmission rate, and outcomes of patients who were treated either medically (non-invasive), or underwent an invasive approach with MitraClip, sMVR, or sMVr using one-way ANOVA and logistic regression. Results A total of 106,015 patients (68±13 years, 42% women) with severe MR and CS were identified. Of these, 88,696 (84%) were treated medically, while 607 (0.6%) underwent MitraClip, 4,528 (4%) underwent sMVR, and 12,184 (12%) underwent sMVr. Majority of patients in all four groups had a high Elixhauser comorbidity score of >6. In-hospital mortality rate was 31% in the medical therapy group, 14% and 17% in the sMVR and sMVr groups subsequently, and 26% in the MitraClip group (p<0.001). The median cost of hospitalization was significantly higher in the MitraClip group ($400,087) compared to the other groups (medical=$140,282, sMVR =$290,456, and sMVr =$353,688, p<0.001). Readmission rates were significantly lower in the sMVR (0.7%) and sMVr (1%) groups compared to the medical therapy (4%) and MitraClip (6%) groups (p<0.001). MitraClip was associated with a higher use of Impella (Odds Ratio (OR) 2.6; 95% Confidence Interval (CI) 1.8–3.8, p<0.001), intra-aortic balloon pump (IABP) (OR 3.8; 95% CI 2.9–5.1, p<0.001), and vasopressors (OR 1.6; 95% CI 1.1–1.7, p<0.001) than sMVR or sMVr. Extracorporeal membrane oxygenation (ECMO) use was more common in sMVR (OR 2.9, 95% CI 2.5–3.4, p<0.001) and sMVr (OR 2.0,95% CI 1.8–2.2, p<0.001) than in MitraClip. In terms of complications, MitraClip was associated with a higher rate of vascular complications (OR 4.2; 95% CI 1.4–12.8, p<0.001); while both sMVR and sMVr had higher association with significant post-operative bleeding (OR 2.3; 95% CI 1.9–2.8, p<0.001) and (OR 2.1; 95% CI 1.9–2.4, p<0.001) respectively. Conclusion Majority of patients in this cohort with severe MR and CS were treated either medically or underwent surgical MV replacement. Although MitraClip improved hospital mortality over medical therapy, it was associated with a higher mortality risk, readmission rate, and cost of hospitalization when compared to sMVR and sMVr. FUNDunding Acknowledgement Type of funding sources: None.

scholarly journals Use of MitraClip system for severe mitral regurgitation in cardiogenic shock: results from a multicentre observational Italian experience (the MITRA-SHOCK study)

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
G Falasconi ◽  
L Pannone ◽  
F Melillo ◽  
M Adamo ◽  
F Ronco ◽  
...  
Keyword(s):  
Mitral Regurgitation ◽  
Hospital Mortality ◽  
Cardiogenic Shock ◽  
Therapeutic Option ◽  
Strong Predictor ◽  
Medical Emergency ◽  
Short Term ◽  
Italian Experience ◽  
Procedural Success ◽  
Mitraclip System

Abstract Background/Introduction Cardiogenic shock (CS) is a medical emergency and a frequent cause of death. CS can be complicated by mitral regurgitation (MR). The presence of at least moderate MR in the setting of shock was associated with about three-times higher odds of 1-year mortality. In the setting of refractory CS, percutaneous mitral valve repair (PMVR) can be a potential therapeutic option. Purpose The aim of the study was to evaluate the efficacy of percutaneous approach of severe MR in patients with CS assessing short-term clinical outcomes. Methods In this study we retrospectively included patients with CS and concomitant severe MR treated with Mitraclip system. We enrolled 28 patients from 5 Italian centers between 2012 and 2019. MitraClip implantation was performed according to each hospital standard care. CS was defined utilizing the Diagnostic Criteria of Cardiogenic Shock used in the SHOCK trial. Procedural success was defined as the presence of moderate or less MR after MitraClip implantation. Results All patients presented at least severe MR. All treated patients were at high surgical risk (STS mortality score 36.4±11.7%). Procedural success was obtained in 24 patients (86%). A mean of 1.71±0.76 clips per patients were implanted. In-hospital complications occurred in 13 patients (46%): 7 minor bleedings (25% of patients), 7 major bleedings (25%), 8 acute kidney injuries (28%). In-hospital mortality was 25% and the reported causes of death were cardiovascular in all patients. At Cox multivariate analysis procedural success was a strong predictor of in-hospital survival (HR 0.11, CI 95% 0.02–0.67, p=0.017). Conclusions PMVR with Mitraclip system in patients with CS and concomitant MR demonstrated high procedural success and acceptable safety. It can be considered a bailout option in this setting of patients with high short-term mortality. Larger prospective studies are needed. In-hospital mortality predictors Funding Acknowledgement Type of funding source: None

Percutaneous Mitral Valve Repair Vs. Stand-Alone Medical Therapy in Patients with Functional Mitral Regurgitation and Heart Failure

2020 ◽  
Vol 21 (1) ◽  
pp. 52-60 ◽  
Author(s):  
Tomás Benito-González ◽  
Rodrigo Estévez-Loureiro ◽  
Pedro A. Villablanca ◽  
Patrizio Armeni ◽  
Ignacio Iglesias-Gárriz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Medical Therapy ◽  
Functional Mitral Regurgitation ◽  
Valve Repair ◽  
Percutaneous Mitral Valve Repair

Abstract 15934: Refractory Cardiogenic Shock in a Patient With Hypertrophic Obstructive Cardiomyopathy and Mitral Regurgitation Necessitating Intra-Aortic Balloon Pump Use

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Indrajeet Mahata ◽  
Michael Faulx ◽  
Snigdha kola ◽  
Sweta Singh
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Cardiogenic Shock ◽  
Pulmonary Edema ◽  
Muscle Protein ◽  
Hypertrophic Obstructive Cardiomyopathy ◽  
Left Ventricular ◽  
Afterload Reduction ◽  
Intra Aortic Balloon Pump ◽  
Refractory Cardiogenic Shock

Introduction: Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disease due to a mutation in cardiac muscle protein resulting in left ventricular wall and septal hypertrophy. The presence of systolic anterior motion (SAM) of the mitral valve leads to dynamic left ventricular outflow tract (LVOT) obstruction. With increasing SAM of the anterior mitral leaflet there is resultant loss of coaptation leading to mitral regurgitation (MR). MR has been associated with HOCM but severe MR physiology causing refractory cardiogenic shock and requiring the use of afterload reduction through intra-aortic balloon pump (IABP) is rare and seems paradoxical to the conventional therapy for HOCM. Case summary: This is a case of 71year old female with HOCM, presenting with worsening shortness of breath. She had pulmonary vascular congestion on Chest X-ray and her Transthoracic Echocardiography demonstrated significant LVOT obstruction with moderate MR. She was being evaluated for myomectomy while being treated medically with beta blocker therapy for HOCM. She decompensated with acute respiratory failure from pulmonary edema, her blood pressure and oxygen saturation dropped. She was intubated. Swan- ganz catheter reading suggested wedge pressures of 22 and elevated pulmonary pressures. MvO2 was 32% and this was suggestive of cardiogenic shock. The Trans-esophageal echocardiogram (TEE) showed normal EF with severe concentric LVH and a moderate to severe (3+) MR due to restricted leaflet motion with regurgitant orifice area being 2.5cm2. At that point her MR was the dominant physiology behind her acute decompensation and cardiogenic shock and hence an IABP was placed for reducing afterload that helped in stabilizing her. Subsequently her wedge pressure and MvO2 improved, she was weaned off the IABP and extubated. The patient is being evaluated for myomectomy and mitral valve repair. Conclusion: This case illustrates complex hemodynamics and a challenging management due to competing MR and HOCM physiologies, too much central volume to offset HOCM may worsen MR and pulmonary edema while too much afterload reduction might worsen the HOCM. The use of IABP in a HOCM patient though seems paradoxical but was necessary in this setting to deal with complex physiologies.

scholarly journals An 86-Year-Old Female with Mitral Regurgitation and Significant Pectus Excavatum

2019 ◽  
Vol 08 (01) ◽  
pp. e37-e40
Author(s):  
Raphael Tasar ◽  
Sophie Tkebuchava ◽  
Mahmoud Diab ◽  
Torsten Doenst
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Minimally Invasive ◽  
Pectus Excavatum ◽  
Heart Team ◽  
Case Description ◽  
Valve Repair ◽  
Minimally Invasive Approach ◽  
Invasive Approach ◽  
Surgical Access

Abstract Background We report the case of minimally invasive mitral valve repair in an 86-year-old female with symptomatic structural mitral regurgitation and severe pectus excavatum. Case Description The case summarizes four areas of repetitive heart team discussions. First, should an 86-year-old patient still be treated invasively? Second, if so, should treatment be interventional or surgical? Third, if surgical, should we replace or repair at that age and fourth which surgical access is best with respect to her chest deformation? Conclusion We chose to surgically repair the valve using a minimally invasive approach. The patient was extubated 3 hours after surgery and discharged after 7 days.

scholarly journals Standardized subannular repair for type IIIb functional mitral regurgitation in a minimally invasive mitral valve surgery setting†

2019 ◽  
Vol 56 (5) ◽  
pp. 968-975 ◽  
Author(s):  
Jonas Pausch ◽  
Eva Harmel ◽  
Christoph Sinning ◽  
Hermann Reichenspurner ◽  
Evaldas Girdauskas
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Minimally Invasive ◽  
Functional Mitral Regurgitation ◽  
Invasive Approach ◽  
Type Iiib ◽  
Duration Of Surgery ◽  
Group A ◽  
Group B

Abstract OBJECTIVES Subannular repair techniques in addition to undersized ring annuloplasty have been developed to address high mitral regurgitation (MR) recurrence rates after mitral valve repair in type IIIb MR. We compared the results of annuloplasty with simultaneous standardized subannular repair versus isolated annuloplasty, focusing on the periprocedural outcomes of minimally invasive procedures. METHODS A consecutive series of 108 patients with type IIIb functional MR with severe signs of bileaflet tethering underwent an annuloplasty + subannular repair (group A; n = 60) versus isolated annuloplasty (group B; n = 48). The primary end point of this prospective, parallel cohort study was death or recurrent MR >2, 1 year postoperatively. The secondary end points were survival and clinical outcomes, with special regard for the minimally invasively treated subgroups. RESULTS Duration of surgery, cardiopulmonary bypass time and aortic cross-clamp time were comparable between both study groups. Procedural outcomes as well as echocardiographic outcome parameters were similar and independent of access (fully endoscopic versus full sternotomy). At the 12-month follow-up, death or MR >2 occurred in 3.3% (2/60) of patients in group A vs in 20.8% (10/48) of patients in group B (P = 0.037). The overall mortality rate during the follow-up period was 1.7% (1/60) in group A vs 12.5% (6/48) in group B (P = 0.041). CONCLUSIONS Standardized realignment of papillary muscles is feasible and reproducible via a minimally invasive approach, resulting in excellent periprocedural outcomes, and has a clear potential to significantly decrease MR recurrence and improve 1-year outcomes compared to isolated annuloplasty.

A Simplified Technique for Correcting Mitral Valve Regurgitation via Minimally Invasive Approach

2018 ◽  
Vol 13 (3) ◽  
pp. 236-238
Author(s):  
Giuseppe Speziale ◽  
Marco Moscarelli
Keyword(s):  
Cardiopulmonary Bypass ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Minimally Invasive ◽  
Mitral Valve Regurgitation ◽  
Valve Regurgitation ◽  
Minimally Invasive Approach ◽  
Invasive Approach ◽  
Repair Techniques

Mitral valve regurgitation may require complex repair techniques that are challenging in minimally invasive and may expose patients to prolonged cardiopulmonary bypass and cross-clamp times. Here, we present a stepwise operative approach that may facilitate the repair of the mitral valve in a minimally invasive fashion and may be carried out even when multiple posterior segments are involved. This how-to-do article presents a method that was performed in 148 patients that were referred to our institution for severe organic mitral regurgitation between 2008 and 2016. At mean ± SD follow-up of 45.5 ± 27 months, freedom from recurrent of mitral regurgitation 2+ or greater and reoperation was 95.2%.

Prophylactic LVAD Enabling High-Risk Mitral Repair—Extending Beyond the Guidelines

2019 ◽  
Vol 14 (6) ◽  
pp. 573-576
Author(s):  
Fadi Hage ◽  
Ali Hage ◽  
Stuart Smith ◽  
A. Dave Nagpal ◽  
Michael W. A. Chu
Keyword(s):  
High Risk ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Cardiogenic Shock ◽  
Clinical Symptoms ◽  
Left Ventricular ◽  
Lv Function ◽  
Assist Device ◽  
Mitral Repair ◽  
Lv Dysfunction

Both surgical and percutaneous mitral repair remain contraindicated in patients with severe degenerative mitral regurgitation (DMR) with severe left ventricular (LV) dysfunction because of inadequate LV reserve and increased LV work with a competent mitral valve. We report a 55-year-old gentleman who presented in cardiogenic shock with missed severe DMR and severe LV dysfunction, in whom we performed a high-risk mitral repair and insertion of a prophylactic CentriMag LV assist device. This innovative approach was found to be successful with significant patient improvement in both LV function and clinical symptoms with a competent mitral valve.

Chordal Tethering: A Unique Cause of Structural Mitral Regurgitation in Dilated Cardiomyopathy

2007 ◽  
Vol 2 (3) ◽  
pp. 122-123
Author(s):  
Saqib Masroor ◽  
Robert Berkowitz ◽  
John C. Alexander
Keyword(s):  
Ventricular Tachycardia ◽  
Mitral Regurgitation ◽  
Minimally Invasive ◽  
Dilated Cardiomyopathy ◽  
Medical Therapy ◽  
Minimally Invasive Approach ◽  
Invasive Approach ◽  
Ventricular Dyssynchrony

Mitral regurgitation in dilated cardiomyopathy is usually considered “functional,” and many such patients are treated medically. Surgery is often offered as a last resort in select patients who have failed medical therapy. We report a patient with dilated cardiomyopathy with ventricular tachycardia and ventricular dyssynchrony and “structural mitral regurgitation” due to chordal tethering, which was managed surgically using a minimally invasive approach.

Minimally Invasive Mitral Valve Replacement Using the Valve-in-valve Technique

2009 ◽  
Vol 4 (4) ◽  
pp. 221-224 ◽  
Author(s):  
Orlando Santana ◽  
Francisco A. Tarrazzi ◽  
Joseph Lamelas
Keyword(s):  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Minimally Invasive ◽  
Pulmonary Edema ◽  
Left Atrium ◽  
Bioprosthetic Valve ◽  
Minimally Invasive Approach ◽  
Invasive Approach ◽  
Valve In Valve ◽  
Bioprosthetic Mitral Valve

A 90-year-old woman with two previous mitral valve replacements, presented with pulmonary edema due to mitral regurgitation from degeneration of her bioprosthetic mitral valve. A minimally invasive approach was used to replace the bioprosthetic mitral valve. During surgery, the bioprosthetic valve was noted to be too adherent to the endocardium of the left atrium, making removal of the prosthesis not only difficult, but also potentially harmful. The new bioprosthetic valve was instead placed using a valve-in-valve approach.

Sign in / Sign up

Export Citation Format

Share Document